MK-8931
Total Payments
$19.7M
Transactions
4,460
Doctors
27
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $364,744 | 17 | 0 |
| 2019 | $1.2M | 192 | 8 |
| 2018 | $4.6M | 1,042 | 18 |
| 2017 | $13.6M | 3,209 | 23 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19.3M | 4,226 | 98.3% |
| Consulting Fee | $333,036 | 183 | 1.7% |
| Travel and Lodging | $6,370 | 23 | 0.0% |
| Food and Beverage | $1,394 | 28 | 0.0% |
Payments by Type
Research
$19.3M
4,226 transactions
General
$340,800
234 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. | Merck Sharp & Dohme Corporation | $14.1M | 0 |
| A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 with a Long Term Double-Blind Extension in Subjects with Mild to Moderate Alzheimer s Disease. Protocol No. MK-8931-017-10 also known as SCH 900931, P07738 | Merck Sharp & Dohme Corporation | $4.1M | 0 |
| REMOTE DATA SENSING TO CONSTRUCT DIGITAL BIOMARKERS ASSOCIATED WITH DISEASE PROGRESSION IN MCI AND AD A PROOF OF CONCEPT STUDY IN PATIENTS UTILIZING SYMPTOMATIC AD THERAPIES | Merck Sharp & Dohme Corporation | $385,000 | 0 |
| A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-8931 when Administered to Subjects with Mild and Moderate Hepatic Insufficiency | Merck Sharp & Dohme Corporation | $246,485 | 0 |
| A Single-Dose, Open-Label, Randomized, Crossover Study to Assess PlasmaPharmacokinetics of MK-8931 and the Effect of Food on MK-8931 PlasmaPharmacokinetics in Healthy Subjects | Merck Sharp & Dohme Corporation | $242,526 | 0 |
| A Test-Retest Reliability Study of Non-Invasive Measures of Autonomic Nervous System Physiology and Actigraphy as Biomarkers of Agitation, Irritability and Anxiety in Alzheimer s Disease and Alzheimer s Disease Related Dementias | Merck Sharp & Dohme Corporation | $143,578 | 0 |
| A Study to Assess the Effect of Multiple Doses of Rifampin on the Single-Dose Pharmacokinetics of MK-8931 in Healthy Adult Subjects | Merck Sharp & Dohme Corporation | $132,111 | 0 |
| A Study to Assess Potential Physical Dependence and Withdrawal Effects after Discontinuation of MK-8931 in Healthy, Non-dependent Subjects | Merck Sharp & Dohme Corporation | $41,774 | 0 |
| A Study to Evaluate the Abuse Potential of MK-8931 SCH 900931 | Merck Sharp & Dohme Corporation | $1,000 | 0 |
Top Doctors Receiving Payments for MK-8931
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Washington, DC | $19.3M | 4,226 |
| , MD | Geriatric Psychiatry | Seattle, WA | $46,900 | 20 |
| , M.D | Neurology | Chicago, IL | $44,088 | 20 |
| , MD | Neurology | Park Ridge, IL | $40,588 | 20 |
| , M.D | Diagnostic Radiology | San Francisco, CA | $31,125 | 19 |
| , MD | Ophthalmology | Philadelphia, PA | $29,434 | 4 |
| , M.D | Diagnostic Radiology | San Francisco, CA | $28,400 | 19 |
| , MD | Neurology | Indianapolis, IN | $24,884 | 21 |
| , MD | Neurology | Boston, MA | $20,446 | 9 |
| , MD | Psychiatry | Los Angeles, CA | $18,993 | 15 |
| , MD | Geriatric Psychiatry | Saint Louis, MO | $13,098 | 16 |
| , MD | Clinical Neurophysiology | Phoenix, AZ | $6,181 | 12 |
| Paul Aisen | Geriatric Medicine | San Diego, CA | $6,128 | 11 |
| , MD | Neurology | Los Angeles, CA | $6,069 | 12 |
| , MD | Diagnostic Radiology | Walnut Creek, CA | $5,100 | 10 |
| , MD | Ophthalmology | Plymouth Meeting, PA | $3,650 | 2 |
| , MD | Dermatopathology | Philadelphia, PA | $3,238 | 3 |
| , M.D | Specialist | Boston, MA | $2,650 | 2 |
| , M.D | Ophthalmology | Baltimore, MD | $2,650 | 2 |
| , M.D | Retina Specialist | Philadelphia, PA | $2,243 | 6 |
| , MD | Dermatology | Chicago, IL | $1,300 | 2 |
| , M.D | Ophthalmology | Durham, NC | $1,125 | 1 |
| , M.D | Dermatology | Bronx, NY | $825.00 | 2 |
| , MD | Dermatology | Baltimore, MD | $725.00 | 2 |
| , MD | Ophthalmology | Plymouth Meeting, PA | $612.50 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $19.7M
- Total Doctors 27
- Transactions 4,460
About MK-8931
MK-8931 is a drug associated with $19.7M in payments to 27 healthcare providers, recorded across 4,460 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $364,744 was paid across 17 transactions to 0 doctors.
The most common payment nature for MK-8931 is "Unspecified" ($19.3M, 98.3% of total).
MK-8931 is associated with 9 research studies, including "A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD." ($14.1M).